Literature DB >> 6804246

Plasma levels of parent drug and metabolites in the intravenous aminopyrine breath test.

U Breyer-Pfaff, M Harder, E H Egberts.   

Abstract

[Dimethylamine-14C]-aminopyrine was given i.v. to 5 healthy volunteers and 5 medical patients in a dose of 1.67 mg/kg, containing 0.02 micro Ci/kg 14C. In 4 volunteers the experiment was repeated using oral administration of aminopyrine. Exhalation of 14CO2 was followed for 6-10 h and plasma levels of the drug and of its metabolites 4-methylamino-antipyrine, 4-amino-antipyrine, 4-acetylamino-antipyrine, 4-formylamino-antipyrine, were measured by thin-layer chromatography. The concentration-time profiles of the metabolites mostly failed to conform to a Bateman function. Areas under the curves from 1 to 6 h after dosing indicated distinct interindividual differences in metabolite patterns even in the absence of disturbed liver function, whereas the intraindividual data were closely reproducible. In most subjects, the area of formylamino-antipyrine exceeded that of the acetyl analogue. The metabolite patterns did not exhibit a consistent relationship to the ratios between 14CO2 half-life in breath and aminopyrine half-life in plasma, which varied from 1.4 to 3.2.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6804246     DOI: 10.1007/BF00542049

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  22 in total

1.  Unaltered metabolism of antipyrine and tolbutamide in fasting man.

Authors:  M M Reidenberg; E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1975-06       Impact factor: 6.875

2.  [AQUALITATIVE STUDIES ON AMINOPYRINE METABOLISM IN MAN].

Authors:  R SCHUEPPEL; K SOEHRING
Journal:  Pharm Acta Helv       Date:  1965-02

3.  Metabolism and excretion of aminopyrine in man.

Authors:  T Goromaru; A Noda; K Matzuyama; S Iguchi
Journal:  Chem Pharm Bull (Tokyo)       Date:  1976-06       Impact factor: 1.645

4.  The fate of aminopyrine (pyramidon) in man and methods for the estimation of aminopyrine and its metabolites in biological material.

Authors:  B B BRODIE; J AXELROD
Journal:  J Pharmacol Exp Ther       Date:  1950-06       Impact factor: 4.030

5.  Assessment of aminopyrine metabolism in man by breath analysis after oral administration of 14C-aminopyrine. Effects of phenobarbital, disulfiram and portal cirrhosis.

Authors:  G W Hepner; E S Vesell
Journal:  N Engl J Med       Date:  1974-12-26       Impact factor: 91.245

6.  Kinetics of CO2-HCO3 minus in normal adult males.

Authors:  H S Winchell; H Stahelin; N Kusubov; B Slanger; M Fish; M Pollycove; J H Lawrence
Journal:  J Nucl Med       Date:  1970-12       Impact factor: 10.057

7.  Aminopyrine demethylation measured by breath analysis in cirrhosis.

Authors:  J Bircher; A Küpfer; I Gikalov; R Preisig
Journal:  Clin Pharmacol Ther       Date:  1976-10       Impact factor: 6.875

8.  [The aminopyrine respiratory test under the acute effect of ethanol. Evaluation of a new method for the measurement of microsomal functions of the liver].

Authors:  V Audétat; R Preisig; J Bircher
Journal:  Schweiz Med Wochenschr       Date:  1977-02-19

9.  Aminopyrine disposition: studies on breath, saliva, and urine of normal subjects and patients with liver disease.

Authors:  G W Hepner; E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1976-12       Impact factor: 6.875

10.  Hybrid information provided by the 14C-aminopyrine breath test. Studies with 14C-monomethylaminoantipyrine in the guinea pig.

Authors:  I Roots; S Nigam; S Gramatzki; G Heinemeyer; A G Hildebrandt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-08       Impact factor: 3.000

View more
  5 in total

1.  Drug pharmacokinetics and the carbon dioxide breath test.

Authors:  E A Lane; I Parashos
Journal:  J Pharmacokinet Biopharm       Date:  1986-02

2.  Pharmacokinetics from a dynamical systems point of view.

Authors:  J M van Rossum; J E de Bie; G van Lingen; H W Teeuwen
Journal:  J Pharmacokinet Biopharm       Date:  1989-06

3.  The specificity of the lymphocyte transformation test in a patient with hypersensitivity reactions to pyrazolone compounds. A 10-week follow-up study before and after rechallenge.

Authors:  N W Brattig; G J Diao; P A Berg
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  A kinetic evaluation of 14CO2 in expired air after 14C-methacetin administration in rats, used for the in vivo study of the metabolism of drugs.

Authors:  D P Thornhill; C Steffen; K J Netter
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Apr-Jun       Impact factor: 2.441

5.  Assessment of drug metabolism in hepatic disease: comparison of plasma kinetics of oral cyclobarbital and the intravenous aminopyrine breath test.

Authors:  U Breyer-Pfaff; H Seyfert; M Weber; E H Egberts
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.